PMID- 11041537
OWN - NLM
STAT- MEDLINE
DCOM- 20010208
LR  - 20190910
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 24
IP  - 6
DP  - 2000 Aug
TI  - Differential behavioural and neurochemical effects of para-methoxyamphetamine and 
      3,4-methylenedioxymethamphetamine in the rat.
PG  - 955-77
AB  - 1. This study was prompted by recent deaths that have occurred after recreational 
      administration of the substituted amphetamine para-methoxyamphetamine (PMA). 
      Because relatively little is known regarding its mechanism(s) of action, its 
      effects on physiological, behavioural and neurochemical parameters were compared 
      with the well known effects of 3,4-methylenedioxymethamphetamine (MDMA). 2. 
      Equivalent doses of PMA (5-20 mg/kg) produced greater hypothermia than MDMA at an 
      ambient temperature of 20 degrees C. At 30 degrees C, PMA continued to evoke 
      hypothermia except the highest dose where hyperthermia ensued. MDMA altered body 
      temperature only at the highest dose where hyperthermia also resulted. 3. At both 
      20 and 30 degrees C, MDMA stimulated locomotor activity whereas PMA had modest 
      effects and then, only at high doses. 4. In vivo chronoamperometry was used to 
      measure the effect of MDMA and PMA on release, and inhibition of uptake, of 
      serotonin (5-HT) and dopamine (DA) in the dorsal striatum of anaesthetised rats. 
      As expected, MDMA evoked release of DA and inhibited uptake of both DA and 5-HT. 
      By contrast, PMA was a relatively weak releasing agent and did not inhibit DA 
      uptake. However, PMA potently inhibited uptake of 5-HT. 5. Taken together these 
      data suggest that the acute adverse effects of PMA are more likely to be 
      associated with alterations in serotonergic rather than dopaminergic 
      neurotransmission.
FAU - Daws, L C
AU  - Daws LC
AD  - Department of Clinical and Experimental Pharmacology, University of Adelaide, 
      Australia. daws@uthscsa.edu
FAU - Irvine, R J
AU  - Irvine RJ
FAU - Callaghan, P D
AU  - Callaghan PD
FAU - Toop, N P
AU  - Toop NP
FAU - White, J M
AU  - White JM
FAU - Bochner, F
AU  - Bochner F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Amphetamines)
RN  - 0 (Hallucinogens)
RN  - 0 (Receptors, Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OVB8F8P39Q (4-methoxyamphetamine)
SB  - IM
MH  - Amphetamines
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Body Temperature/drug effects
MH  - Hallucinogens/adverse effects/*pharmacology
MH  - Hypothermia/*chemically induced
MH  - Motor Activity/*drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/adverse effects/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Serotonin/drug effects/physiology
EDAT- 2000/10/21 11:00
MHDA- 2001/03/03 10:01
CRDT- 2000/10/21 11:00
PHST- 2000/10/21 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2000/10/21 11:00 [entrez]
AID - S0278-5846(00)00113-5 [pii]
AID - 10.1016/s0278-5846(00)00113-5 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. doi: 
      10.1016/s0278-5846(00)00113-5.